Company Description
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers.
Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia.
Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
| Country | United States |
| Founded | 2020 |
| IPO Date | Sep 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Tiago Marques |
Contact Details
Address: 1111 Lincoln Road, Suite 500 Miami Beach, Florida 33139 United States | |
| Phone | 786 977 3380 |
| Website | pasithea.com |
Stock Details
| Ticker Symbol | KTTA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001841330 |
| CUSIP Number | 70261F103 |
| ISIN Number | US70261F2020 |
| Employer ID | 85-1591963 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Tiago Reis Marques M.D., Ph.D. | Chief Executive Officer and Director |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder, MD and Executive Chairman |
| Daniel H. Schneiderman | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 24, 2025 | ARS | Filing |
| Jul 24, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 14, 2025 | PRE 14A | Other preliminary proxy statements |
| Jul 11, 2025 | 8-K | Current Report |
| Jun 27, 2025 | 8-K | Current Report |
| Jun 20, 2025 | 8-K | Current Report |
| Jun 20, 2025 | 424B5 | Filing |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | 144 | Filing |